June 12 – 17, 2022
The structural protein of rotavirus (RV) VP6 can self-assemble into tubular polymeric structures under specific conditions of pH and ionic strength when expressed in recombinant systems. Previous studies have shown that RV VP6 nanotubes (VP6NT) have an adjuvant effect on the immunogenicity of norovirus virus-like particles (VLPs) in mice (Blazevic et al., 2011; Malm et al., 2016). The present study focused on the determination of adjuvant activity of VP6NT on the immunogenicity of monomers of the viral envelope (E) protein or of Zika virus (ZikV) VLPs. ZikV infection can cause congenital malformations in fetuses and the Guillain-Barré syndrome in adults, as the most severe consequences. To date, there is no treatment or vaccine available against ZikV. Several vaccine candidates against this virus have been reported and E protein has been selected as the primary antigenic determinant.
Please click Download on the upper right corner to see the full abstract.
Arturo Liñan, Ana Ruth Pastor, Selene J. Uribe-Romero, Mabel Rodriguez, Octavio T. Ramirez, and Laura A. Palomares, "Rotavirus VP6 nanotubes show an antigen form-dependent adjuvant activity: Zika virus envelope protein monomer vs Zika virus-like particles" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/120